Healthcare provider profile · identity verified

Michael E Ainsworth, MD

Allopathic & Osteopathic Physicians|Family Medicine · DECATUR, IN · NPI 1629058698

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Michael E Ainsworth, MD received $95.07 in general payments during 2025 across 6 reported records.

Axsome Therapeutics, Inc. accounted for 70.2% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Ozempic by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$95.07

6 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$66.72	70.2%	4	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$14.69	15.4%	1	2025
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$13.66	14.4%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$95.07	6

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$66.72	4	2025
Source payment records 2025-01-15 · Axsome Therapeutics, Inc. · $14.20 · Open Payments source 2025-04-02 · Axsome Therapeutics, Inc. · $15.84 · Open Payments source 2025-05-20 · Axsome Therapeutics, Inc. · $21.77 · Open Payments source 2025-06-17 · Axsome Therapeutics, Inc. · $14.91 · Open Payments source
AIRSUPRA Normalized: airsupra	Drug	AstraZeneca Pharmaceuticals LP	$14.69	1	2025
Source payment records 2025-04-23 · AstraZeneca Pharmaceuticals LP · $14.69 · Open Payments source
Wegovy Normalized: wegovy	Drug	Novo Nordisk Inc	$13.66	1	2025
Source payment records 2025-03-12 · Novo Nordisk Inc · $13.66 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	50	14
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	96	25
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Rybelsus open payments reported associated product	CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076	Rybelsus · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	756	211
Amlodipine Besylate	Amlodipine Besylate	531	153
Metoprolol Succinate	Metoprolol Succinate	530	157
Atorvastatin Calcium	Atorvastatin Calcium	516	159
Lisinopril	Lisinopril	453	139
Omeprazole	Omeprazole	346	101
Pantoprazole Sodium	Pantoprazole Sodium	334	93
Metformin Hcl	Metformin Hcl	327	102
Simvastatin	Simvastatin	303	84
Famotidine	Famotidine	297	86
Gabapentin	Gabapentin	294	76
Rosuvastatin Calcium	Rosuvastatin Calcium	282	91
Hydrochlorothiazide	Hydrochlorothiazide	268	77
Tamsulosin Hcl	Tamsulosin Hcl	263	83
Trazodone Hcl	Trazodone Hcl	257	80
Pravastatin Sodium	Pravastatin Sodium	250	69
Potassium Chloride	Potassium Chloride	249	71
Losartan Potassium	Losartan Potassium	230	67
Sertraline Hcl	Sertraline Hcl	230	43
Furosemide	Furosemide	212	57
Alendronate Sodium	Alendronate Sodium	211	63
Citalopram Hbr	Citalopram Hydrobromide	204	58
Prednisone	Prednisone	185	132
Montelukast Sodium	Montelukast Sodium	182	39
Duloxetine Hcl	Duloxetine Hcl	178	47
Allopurinol	Allopurinol	167	48
Eliquis	Apixaban	164	44
Albuterol Sulfate Hfa	Albuterol Sulfate	154	69
Finasteride	Finasteride	152	40
Carvedilol	Carvedilol	149	43
Metoprolol Tartrate	Metoprolol Tartrate	140	44
Bupropion Xl	Bupropion Hcl	134	35
Buspirone Hcl	Buspirone Hcl	131	33
Ezetimibe	Ezetimibe	130	42
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	128	27
Spironolactone	Spironolactone	126	38
Clopidogrel	Clopidogrel Bisulfate	120	43
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	115	36
Meloxicam	Meloxicam	114	45
Bumetanide	Bumetanide	111	39
Escitalopram Oxalate	Escitalopram Oxalate	111	39
Fluoxetine Hcl	Fluoxetine Hcl	110	28
Alprazolam	Alprazolam	107	37
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	105	28
Hydralazine Hcl	Hydralazine Hcl	100	35
Pioglitazone Hcl	Pioglitazone Hcl	100	26
Mounjaro	Tirzepatide	99	19
Tramadol Hcl	Tramadol Hcl	98	19
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	97	23
Ozempic	Semaglutide	96	25
Warfarin Sodium	Warfarin Sodium	91	26
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	86	25
Jardiance	Empagliflozin	83	23
Memantine Hcl	Memantine Hcl	83	suppressed
Lovastatin	Lovastatin	79	21
Valsartan	Valsartan	76	27
Diclofenac Sodium	Diclofenac Sodium	75	36
Oxybutynin Chloride Er	Oxybutynin Chloride	75	26
Ropinirole Hcl	Ropinirole Hcl	67	20
Irbesartan	Irbesartan	66	17
Januvia	Sitagliptin Phosphate	65	20
Pregabalin	Pregabalin	65	19
Atenolol	Atenolol	64	19
Metformin Hcl Er	Metformin Hcl	64	22
Doxycycline Hyclate	Doxycycline Hyclate	61	46
Celecoxib	Celecoxib	59	19
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	59	12
Mirtazapine	Mirtazapine	57	20
Farxiga	Dapagliflozin Propanediol	50	14
Fluticasone Propionate	Fluticasone Propionate	50	21
Verapamil Er	Verapamil Hcl	47	13
Oxybutynin Chloride	Oxybutynin Chloride	45	13
Esomeprazole Magnesium	Esomeprazole Magnesium	44	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	43	21
Lamotrigine	Lamotrigine	43	12
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	43	12
Cephalexin	Cephalexin	42	36
Quetiapine Fumarate	Quetiapine Fumarate	40	suppressed
Synthroid	Levothyroxine Sodium	40	13
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	39	12
Benazepril Hcl	Benazepril Hcl	38	suppressed
Donepezil Hcl	Donepezil Hcl	38	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	38	11
Nabumetone	Nabumetone	38	suppressed
Paroxetine Hcl	Paroxetine Hcl	38	11
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	37	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	36	14
Xarelto	Rivaroxaban	36	11
Estradiol	Estradiol	35	19
Naproxen	Naproxen	35	19
Amitriptyline Hcl	Amitriptyline Hcl	34	suppressed
Nifedipine Er	Nifedipine	34	suppressed
Primidone	Primidone	34	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	34	suppressed
Breo Ellipta	Fluticasone/Vilanterol	33	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	33	suppressed
Mometasone Furoate	Mometasone Furoate	32	15
Amoxicillin	Amoxicillin	30	22
Clonazepam	Clonazepam	30	suppressed
Glipizide Er	Glipizide	30	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	29	12
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	29	suppressed
Gemfibrozil	Gemfibrozil	28	suppressed
Fentanyl	Fentanyl	27	suppressed
Lorazepam	Lorazepam	27	suppressed
Tizanidine Hcl	Tizanidine Hcl	27	suppressed
Cefdinir	Cefdinir	26	26
Metolazone	Metolazone	26	16
Midodrine Hcl	Midodrine Hcl	25	15
Hydroxyzine Hcl	Hydroxyzine Hcl	24	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	24	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	24	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	23	suppressed
Solifenacin Succinate	Solifenacin Succinate	23	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	23	suppressed
Tresiba Flextouch U-100	Insulin Degludec	23	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Divalproex Sodium	Divalproex Sodium	22	suppressed
Glipizide	Glipizide	22	suppressed
Meclizine Hcl	Meclizine Hcl	22	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	22	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	21	18
Fenofibrate	Fenofibrate	21	suppressed
Klor-Con M20	Potassium Chloride	21	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	21	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	21	11
Propranolol Hcl Er	Propranolol Hcl	21	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	20	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	20	suppressed
Ipratropium Bromide	Ipratropium Bromide	19	suppressed
Fenofibrate	Fenofibrate,micronized	18	suppressed
Incruse Ellipta	Umeclidinium Bromide	18	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	11
Amiodarone Hcl	Amiodarone Hcl	17	suppressed
Azithromycin	Azithromycin	17	16
Clonidine Hcl	Clonidine Hcl	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Fluconazole	Fluconazole	17	16
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	15
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	17
Testosterone Cypionate	Testosterone Cypionate	17	suppressed
Topiramate	Topiramate	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	16	suppressed
Hydrocortisone	Hydrocortisone	16	suppressed
Modafinil	Modafinil	16	suppressed
Novolog Flexpen	Insulin Aspart	16	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	15	suppressed
Folic Acid	Folic Acid	15	suppressed
Lansoprazole	Lansoprazole	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	14	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	14	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Mupirocin	Mupirocin	14	11
Promethazine Hcl	Promethazine Hcl	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Glimepiride	Glimepiride	13	suppressed
Levofloxacin	Levofloxacin	13	11
Torsemide	Torsemide	13	suppressed
Ultra-Fine Micro Pen Needle	Pen Needle, Diabetic	13	suppressed
Zolmitriptan	Zolmitriptan	13	suppressed
Budesonide Dr	Budesonide	12	suppressed
Carbamazepine Er	Carbamazepine	12	suppressed
Dexlansoprazole Dr	Dexlansoprazole	12	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	12	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	12	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Rexulti	Brexpiprazole	12	suppressed
Tadalafil	Tadalafil	12	suppressed
Terazosin Hcl	Terazosin Hcl	12	suppressed
Avonex (4 Pack)	Interferon Beta-1a	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	11
Pen Needle	Pen Needle, Diabetic	11	suppressed
Raloxifene Hcl	Raloxifene Hcl	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Tresiba Flextouch U-200	Insulin Degludec	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$95.07 · 6 records	Axsome Therapeutics, Inc.	AIRSUPRA, Auvelity, Wegovy	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error